T-lymphocyte Alloresponses of Campath-1H-Treated Kidney Transplant Patients
Authors:
- Debra D. BloomDBDebra D. Bloom
- Huaizhong HuHHHuaizhong Hu
- John H. FechnerJFJohn H. Fechner
- Stuart J. KnechtleSKStuart J. Knechtle
- 15 January 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 81 (1) , 81-87
Abstract
Background.: Kidney transplant patients given Campath-1H (Alemtuzumab) immunodepletion therapy and long-term rapamycin monotherapy have excellent graft survival and function at three years. As an initial step in understanding the characteristics of repopulated T lymphocytes in these patients, we performed several assays to assess alloreactivity. Methods.: We measured T-cell responses using CFSE-labeled recipient lymphocytes in a direct one-way MLR, and also analyzed the kinetics of expression of IFN-γ. We examined the T-cell responses of Campath-treated transplant patients on monotherapy versus those treated with anti-CD25 (Basiliximab) induction therapy and maintenance immunosuppression consisting of cyclosporine A, mycophenolate mofetil, and steroids. Results.: On average, proliferative responses to donor antigen were equal between Campath and control groups. However, the Campath group displayed a greater response to third party compared to donor antigen (CD3 + P =0.04, CD4 + P =0.07, CD8 + P + P =0.69, CD4 + P =0.72, CD8 + P =0.60). Interestingly, more Campath patients (4 of 15) than control patients (0 of 8) displayed donor specific unresponsiveness as gauged by IFN-γ expression and T-cell proliferation ( P =0.15). Conclusions.: These studies suggest that Campath-1H in conjunction with rapamycin monotherapy retains intact immune responses to third party alloantigen, yet may promote hyporesponsiveness to donor antigen.Keywords
This publication has 18 references indexed in Scilit:
- Non-specific immunosuppressants in the treatment of multiple sclerosisClinical Neurology and Neurosurgery, 2004
- Campath-1H immunosuppressive therapy reduces incidence and intensity of acute rejection in intestinal and multivisceral transplantationTransplantation Proceedings, 2004
- Treatment of refractory autoimmune diseases with ablative immunotherapyAutoimmunity Reviews, 2004
- RESULTS FROM A HUMAN RENAL ALLOGRAFT TOLERANCE TRIAL EVALUATING THE HUMANIZED CD52-SPECIFIC MONOCLONAL ANTIBODY ALEMTUZUMAB (CAMPATH-1H)Transplantation, 2003
- Campath-1H Induction Plus Rapamycin Monotherapy for Renal Transplantation: Results of a Pilot StudyAmerican Journal of Transplantation, 2003
- Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantationBlood, 2003
- Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?Bone Marrow Transplantation, 2002
- Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumabBlood, 2002
- CAMPATH-1H in multiple sclerosisMultiple Sclerosis Journal, 1996
- Reshaping human antibodies for therapyNature, 1988